94 results
8-K
EX-2.1
RVLPQ
RVL Pharmaceuticals plc
27 Nov 23
Bankruptcy or Receivership
4:06pm
and exclusive responsibility for the satisfaction and payment of any tax obligations imposed on such holder by any governmental unit, including income
8-K
EX-10.1
RVLPQ
RVL Pharmaceuticals plc
20 Oct 23
Entry into a Material Definitive Agreement
5:00pm
responsibility for the resolution of any EEA Financial Institution.
“Effective Date” means the date on which the conditions set forth in Section 5.01 … administrative authority having responsibility for the resolution of any UK Financial Institution.
“Uniform Commercial Code” means the Uniform Commercial Code
8-K
EX-99.1
RVLPQ
RVL Pharmaceuticals plc
13 Oct 23
Termination of a Material Definitive Agreement
4:15pm
and exclusive responsibility for the satisfaction and payment of any tax obligations imposed on such holder by any governmental unit, including income
8-K
EX-10.1
RVLPQ
RVL Pharmaceuticals plc
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
) Insurance. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks
424B5
RVLPQ
RVL Pharmaceuticals plc
17 Aug 23
Prospectus supplement for primary offering
4:05pm
with this offering. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you … ’ Duties
Our directors have certain statutory and fiduciary duties. All of our directors have equal and overall responsibility for our management (although
CORRESP
tx6n2a0im027k
27 Jul 23
Correspondence with SEC
12:00am
UPLOAD
91dwa
15 Jun 23
Letter from SEC
12:00am
8-K
EX-99.1
k7zk27muz0bt xnnxx
18 Oct 22
RVL Pharmaceuticals plc Announces Preliminary Third Quarter 2022 UPNEEQ® Net Product Sales
7:11am
8-K
EX-99.1
23enwy
7 Jul 22
RVL Pharmaceuticals plc Announces Preliminary Second Quarter 2022 UPNEEQ® Net Product Sales Results
7:33am
8-K
c8xwewa pvzr
11 Apr 22
Departure of Directors or Certain Officers
4:33pm
8-K
EX-99.1
hnhqjbtj8k5s
6 Apr 22
RVL Pharmaceuticals plc Announces Preliminary First Quarter 2022 UPNEEQ® Net Product Sales Results
9:04am
8-K
EX-99.1
1dekrwad3tt7bzbtr1dl
19 Jan 22
Results of Operations and Financial Condition
7:07am